Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Webinars / 2024 / Addressing Clinical Needs in Precision Oncology with Rapid NGS
Thermo Fisher Scientific

Addressing Clinical Needs in Precision Oncology with Rapid NGS: Experiences with the Oncomine Dx Express Test

In this webinar, two laboratories share their journey in addressing these challenges and their decision to implement the Oncomine Dx Express Test. Explore how this rapid and automated NGS assay has empowered these laboratories to analyze challenging samples, streamline workflows, and deliver timely, high-quality genomic profiling to enhance patient care.

06/13/2024 11am ET

Share

Register here

June 13, 2024 - 11am ET

Genomic profiling plays a critical role in precision oncology. However, in the real-world, it is often constrained by challenges such as very small biopsies, sample quality, and turnaround time. 

In this webinar, two laboratories share their journey in addressing these challenges and their decision to implement the Oncomine Dx Express Test. Explore how this rapid and automated NGS assay has empowered these laboratories to analyze challenging samples, streamline workflows, and deliver timely, high-quality genomic profiling to enhance patient care.

Webinar learning objectives:

  • Reasons for implementing Oncomine Dx Express Test for in-house genomic profiling from two molecular pathology laboratories in Europe

  • Real-world experiences including its utility, integration into the laboratory workflow, and analysis of clinical samples, such as challenging samples and liquid biopsies

  • Case studies where turnaround time played a critical role

*For In Vitro Diagnostic Use. Not available in all countries including the United States.

Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology, the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Oncomine Dx Express Test also detects deletions, insertions, substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

More Webinars

December 9, 2024

State of the Nation: Interrogating the Benefits and Obstacles to Digitization and AI Adoption

October 28, 2024

Optimizing Cancer Care through Strategic Selection of NGS Testing Platforms: Balancing Panel Size with DNA Input Challenges

Subspecialties Omics Oncology Precision medicine

August 28, 2024

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.